Creative Planning’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Creative Planning’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,611	Closed	-$24K	–	4068
2017 Q2	$24K	Sell	7,611 -389	-5%	-$1.23K	﹤0.01%	3065
2017 Q1	$27K	Buy	8,000 +2,600	+48%	+$7.32K	﹤0.01%	2933
2016 Q4	$16K	Buy	5,400 +400	+8%	+$1.42K	﹤0.01%	3238
2016 Q3	$29K	Hold	5,000	–	–	﹤0.01%	2777
2016 Q2	$15K	Hold	5,000	–	–	﹤0.01%	2993
2016 Q1	$27K	Hold	5,000	–	–	﹤0.01%	2555
2015 Q4	$59K	Buy	+5,000	New	+$57.2K	﹤0.01%	1988
2014 Q3	–	Sell	-200	Closed	-$5K	–	4213
2014 Q2	$5K	Buy	+200	New	+$3.63K	﹤0.01%	3256

Other funds holding DRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Creative Planning's DRNA Position: Q3 2017 in Review

Creative Planning sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2017, closing a stake of 7,611 shares — an estimated $24K sold.

Creative Planning first reported a position in DRNA in Q2 2014 and held it in 8 quarters. The position peaked at $59K in Q4 2015. 37 funds tracked by Wall St. Rank hold DRNA as of Q3 2017.

Creative Planning reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 7,611 Dicerna Pharmaceuticals, Inc. shares in Q3 2017, an estimated $24K.
Creative Planning first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 8 quarters.
Creative Planning's Dicerna Pharmaceuticals, Inc. position peaked at $59K in Q4 2015.
37 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.